公开(公告)号：US20240116900A1

公开(公告)日：2024-04-11

申请号：US18250466

申请日：2021-10-29

Applicant: NOVARTIS AG

Inventor： Simona COTESTA ,  Heng GE ,  Marc GERSPACHER ,  Catherine LEBLANC ,  Bo LIU ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Tanja MEISTER ,  Christophe MURA ,  Pascal RIGOLLIER ,  Nadine SCHNEIDER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Lijun XUE ,  Marie-Anne LOZAC'H ,  Ross STRANG

IPC: C07D403/14

CPC classification number: C07D403/14

Abstract: Provided are crystalline forms of a KRAS G12C inhibitor compound and to processes for their preparation. Furthermore, provided is pharmaceutical composition comprising said crystalline forms, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition can be used as a medicament, in particular for the treatment of cancer, and KRAS G12C-mutant cancer.